The safety Survey of pneumonitis induced by the combination of platinum, pemetrexed and pembrolizumab in chemo-naive non-small cell lung cancer patient in the real-world setting

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 11 Jan 2022

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Pembrolizumab (Primary) ; Pemetrexed (Primary) ; Platinum complexes (Primary)
Indications Adenocarcinoma; Non-small cell lung cancer
Focus Adverse reactions
Acronyms SUSPECT

30 Apr 2021 Status changed from active, no longer recruiting to completed.
20 Apr 2021 Results published in the European Journal of Cancer
24 Mar 2020 Status changed from not yet recruiting to active, no longer recruiting.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com